- freely available
Design, Synthesis, and Biological Evaluation of PKD Inhibitors
AbstractProtein kinase D (PKD) belongs to a family of serine/threonine kinases that play an important role in basic cellular processes and are implicated in the pathogenesis of several diseases. Progress in our understanding of the biological functions of PKD has been limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 was recently reported as the first potent and kinase-selective inhibitor for this enzyme. For structure-activity analysis purposes, a series of analogs was prepared and their in vitro inhibitory potency evaluated.
Share & Cite This Article
George, K.M.; Frantz, M.-C.; Bravo-Altamirano, K.; LaValle, C.R.; Tandon, M.; Leimgruber, S.; Sharlow, E.R.; Lazo, J.S.; Wang, Q.J.; Wipf, P. Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics 2011, 3, 186-228.View more citation formats
George KM, Frantz M-C, Bravo-Altamirano K, LaValle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P. Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics. 2011; 3(2):186-228.Chicago/Turabian Style
George, Kara M.; Frantz, Marie-Céline; Bravo-Altamirano, Karla; LaValle, Courtney R.; Tandon, Manuj; Leimgruber, Stephanie; Sharlow, Elizabeth R.; Lazo, John S.; Wang, Q. Jane; Wipf, Peter. 2011. "Design, Synthesis, and Biological Evaluation of PKD Inhibitors." Pharmaceutics 3, no. 2: 186-228.
Notes: Multiple requests from the same IP address are counted as one view.